NCT02398604View on ClinicalTrials.gov

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

PHASE1TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions

Hypoplastic Left Heart Syndrome

Interventions

DRUG

Allo-hMSCs

Allogeneic Human Mesenchymal Stem Cells

DRUG

Placebo

Placebo

Trial Locations (2)

21201

University of Maryland Medical Center, Baltimore

21287

Johns Hopkins Hospital, Baltimore

Sponsors

Lead Sponsor

Longeveron Inc.

All Listed Sponsors

lead

Longeveron Inc.

INDUSTRY

NCT02398604 - Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome | Biotech Hunter | Biotech Hunter